Beginning at diagnosis, #BreastCancer impacts all aspects of patients’ lives.

Understanding and managing these long-term impacts is critical for supporting patients during treatment and throughout #survivorship .

Click here to learn more: e.lilly/49tUD2S

#AACR24 attendees - Thank you to everyone who joined us in San Diego and online! #CancerResearch

Visit the Loxo@Lilly congress hub to see the research we presented at this year’s meeting: e.lilly/3vt6MY4

#ClinicalTrials #KRAS #Nectin4 #SMARCA2

At #AACR24 , in collaboration with Foghorn Therapeutics, we’re excited to share the first presentation of preclinical data for an oral BRM (SMARCA2) selective inhibitor.

See the analysis here: e.lilly/3PGkyxo

#CancerResearch #PrecisionMedicine #SMARCA2

At #AACR24 , we’re presenting preclinical data for an anti-Nectin-4 antibody drug conjugate (ADC) with a novel topoisomerase I inhibitor payload.

See the data here: e.lilly/43ERuvL

#ADCs #Nectin4 #CancerResearch

#AACR24 | Poster Presentation

Preclinical analysis of an orally administered, non-covalent, #KRAS G12D inhibitor that is selective against wild-type (WT) #KRAS .

View the presentation here: e.lilly/3PItAtz

#CancerResearch

#AACR24 - Learn about the EXCEED trial, a phase 1 trial investigating a #Nectin4 targeted antibody drug conjugate (ADC) in advanced or metastatic urothelial cancer and other solid tumors.

Trial in progress poster: e.lilly/3IWpuKx

#CancerResearch #ClinicalTrials #ADCs

We’re excited to join the #CancerResearch community in San Diego for the AACR Annual Meeting 2024!

Visit us onsite at the Loxo@Lilly booth (3237) or click here to explore our #AACR24 congress hub: e.lilly/3vt6MY4

#ClinicalTrials #KRAS #Nectin4 #SMARCA2 (BRM)

A #BreastCancer Survivor describes a person who is anywhere along the trajectory from #BreastCancer diagnosis throughout their life. Addressing survivors’ long-term needs is critical for providing quality healthcare.

Learn more here: e.lilly/4ayFTjY

#Survivorship #BCSM

HCPs - How do you approach shared decision making in #CLL ?

Dr. Lindsey Roeker and Dr. Meghan Thompson discuss key factors to consider when selecting treatment options and how to empower patients through shared decision making. #leusm

Click here to watch: e.lilly/3Tym9pT

Advances in #PrecisionMedicine underscore the importance of #ComprehensiveGenomicProfiling (CGP) as standard of care for patients with #cancer .

Hear from Dr. Brandon Sheffield about the benefits of CGP and the advantages of insourcing biomarker testing: e.lilly/3PrFKqA

Thank you to all those who joined us at #ELCC24 !

Visit the Loxo@Lilly congress hub to see the research we presented in RET fusion-positive non-small cell lung cancer: e.lilly/4ajw0a4

#PrecisonMedicine #LCSM #NSCLC #CancerResearch

At #ELCC24 : Final analysis from the LIBRETTO-001 trial, evaluating a RET kinase inhibitor in patients w/ RET fusion-positive non-small cell lung cancer ( #NSCLC ).

See the data here: e.lilly/3vfzLOS

#PrecisionMedicine #LungCancer #LCSM

For patients with #EarlyBreastCancer on oral #AdjuvantTherapy , proactive, individualized decisions regarding treatment duration and dose modifications are important to ensure best possible clinical outcomes.

Click here to learn more: e.lilly/43v43Ke

#BCSM #BreastCancer

At #ELCC24 , check out our poster presentation to learn about continued treatment w/ a RET kinase inhibitor beyond progression in RET fusion-positive non-small cell #lungcancer (NSCLC).

Results from the LIBRETTO-001 trial: e.lilly/4a5I3rQ

#PrecisionMedicine #NSCLC #LCSM

At #ELCC24 , we're presenting additional analysis from LIBRETTO-001, a phase I/II study of a RET kinase inhibitor in patients with RET fusion-positive #NSCLC .

Learn more about our presentations at this year's meeting: e.lilly/4ajw0a4

#LungCancer #LCSM #CancerResearch

The EXCEED Trial | NOW ENROLLING

Phase 1 trial of our investigational #Nectin4 targeted antibody drug conjugate (ADC) in recurrent, advanced or metastatic solid tumors. #CancerResearch #ClinicalTrials #ADCs

Click here for detailed trial/enrollment info: e.lilly/49kkcUX

#BreastCancer mortality has, in general, ⬇ by 58% in the last 50 yrs, largely due to improved tx options for stages I-III.

To maximize #EarlyBreastCancer (EBC) outcomes, supporting patients throughout the entire treatment journey is vital.

Learn more: e.lilly/3Vk6hdb

As #PrecisionMedicine 🎯🩺 continues to advance, a key question for #oncology providers is how to improve access to #ComprehensiveGenomicProfiling (CGP).

Learn how we’re working to address this issue & improve access through collaborations w/ our partners: e.lilly/3TQqaYv

We're excited to join the #CancerResearch community at the AACR Annual Meeting and look forward to presenting new preclinical data from our early phase #oncology pipeline.

Learn more about our #AACR24 presentations here: e.lilly/3P7WNO9

Updates to the NCCN Guidelines® for thyroid carcinoma have been recently published, including new category 1 updates for patients w/ RET-mutant #MedullaryThyroidCancer (MTC).

To access the latest version, visit: nccn.org

#PrecisionMedicine #ThyroidCancer